Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Iovance Biotherapeutics, Inc. due to allegations of violations of federal securities laws, particularly regarding misleading statements about the company's growth potential and operational capabilities [3][5]. Group 1: Legal Investigation and Class Action - A federal securities class action has been filed against Iovance, with a deadline of July 14, 2025, for investors to seek the role of lead plaintiff [3]. - The firm encourages investors who suffered losses in Iovance between May 9, 2024, and May 8, 2025, to discuss their legal rights [1][3]. Group 2: Financial Performance and Stock Impact - On July 25, 2024, Iovance announced a reduction in its revenue guidance for the full fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and a variable pace of treatment initiation [6]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in just one day [6]. Group 3: Company Background - Iovance Biotherapeutics, Inc. is involved in the biotherapeutics sector, focusing on innovative treatments, but has faced scrutiny regarding its operational effectiveness and market demand [5]. - Faruqi & Faruqi, LLP has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [4].

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=152606&from=3 C ...

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Core Viewpoint - Iovance Biotherapeutics, Inc. is facing a class action lawsuit due to allegations of providing misleading statements about its growth potential while failing to meet revenue expectations, leading to a significant drop in stock price [1][2]. Summary by Sections Allegations - The complaint alleges that Iovance made overwhelmingly positive statements to investors while concealing material adverse facts about its growth potential [1]. - Key issues included the company's inability to generate demand and capitalize on existing demand for its treatments through approved treatment centers [1]. - Following the announcement of reduced revenue guidance for fiscal year 2024, the stock price fell dramatically from $3.17 to $1.75, a decline of approximately 44.8% in one day [1]. Financial Performance - On July 25, 2024, Iovance reported its second-quarter financial results and lowered its revenue guidance for the full fiscal year 2024 [1]. - The company cited three main reasons for the lowered guidance: scheduled maintenance of the iCTC, lower-than-expected Proleukin sales, and the variable pace of treatment initiation by ATCs [1]. Next Steps for Shareholders - Shareholders who purchased IOVA shares during the specified class period are encouraged to register for the class action by July 14, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Iovance Biotherapeutics (IOVA) FY 2025 Conference June 11, 2025 01:20 PM ET Speaker0 Good afternoon everyone. Thanks so much for joining us. I'm really pleased to be joined by Brian Gasman, EVP of Medical Affairs, and Dan Kirby, CCO of Iovance. Thank you both for joining us. Speaker1 Thank you. Speaker0 Dan, maybe I can start with you here. Given Amtagni has been on the market now for over a year, what have been the biggest learnings from this launch? And what has been maybe easier in some ways, or what has ...

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Iovance investors who were adversely affected by alleged securities fraud between May 9, 2024 and May 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/iovance-biotherapeutic ...

Financial Data and Key Metrics Changes - The company reported a cash position of $366 million as of March 31, 2025, with total product revenue exceeding $210 million [19] - The anticipated full-year burn for 2025 is expected to be under $300 million, with gross margins projected to increase to over 78% in the coming years [39] Business Line Data and Key Metrics Changes - Iovance has two approved products, Amtagvi and Proleukin, with over 1,000 patients treated commercially and clinically [18] - The company has 11 ongoing clinical trials and three regulatory filings currently under review outside the U.S. [19] Market Data and Key Metrics Changes - The global advanced melanoma patient treatment opportunity is estimated at about 70,000 patients [18] - The addressable market for non-small cell lung cancer is significant, with 50,000 patients annually in the U.S. and an even larger number in targeted European Union markets [32] Company Strategy and Development Direction - Iovance aims to expand its market presence for Ampagvi into other regions, with regulatory approvals planned for the UK, EU, and Canada in 2025, and Australia and Switzerland in 2026 [27] - The company is focusing on utilizing Till therapy in earlier lines of treatment, as evidenced by the initiation of the Tovan C O One global phase three trial [30] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significant unmet medical need in cancer treatment, particularly for solid tumors, and the potential of Till therapy to provide durable responses [32] - The company emphasized its strong financial position and sufficient cash runway into the second half of 2026, indicating confidence in its growth trajectory [39] Other Important Information - Iovance has received multiple priority designations from the FDA, indicating a strong pipeline and regulatory support [19] - The company has onboarded over 80 treatment centers as of May 8, 2025, enhancing its commercial launch capabilities [18] Q&A Session Summary - There were no questions submitted during the Q&A session, indicating either satisfaction with the presentation or a lack of inquiries from stockholders [40]

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Company Overview - Iovance Biotherapeutics, Inc. is focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients [2] - The company aims to be a global leader in TIL therapies, utilizing the human immune system to target diverse cancer cells [2] - Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, showcasing the company's commitment to continuous innovation in cell therapy [2] Upcoming Events - Senior leadership of Iovance Biotherapeutics will present at the Goldman Sachs Global Healthcare Conference on June 11, 2025, at 1:20 p.m. ET [1] - The presentation will be available via live and archived webcasts on the company's investor relations website [1] Product Development - The Iovance TIL platform has shown promising clinical data across multiple solid tumors, indicating potential for future growth and development [2] - The company is also exploring gene-edited cell therapy as part of its innovation strategy [2]

Core Viewpoint - A class action securities lawsuit has been filed against Iovance Biotherapeutics, Inc. due to alleged securities fraud affecting investors between May 9, 2024, and May 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Iovance provided misleading statements about its growth potential while concealing adverse facts regarding its ability to meet demand for its treatments [2]. - On July 25, 2024, Iovance announced a reduction in its revenue guidance for fiscal year 2024, attributing this to maintenance issues, lower-than-expected Proleukin sales, and the variable pace of treatment initiation at approved centers [2]. - Following the announcement, Iovance's stock price plummeted from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decline of approximately 44.8% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until July 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].